What question did this study set out to answer?

To evaluate the ability of asiaticoside to enhance the effectiveness of MSLN-targeted CAR-T cells in treating ovarian cancer.

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

View Full Paper

Ask AI

Bookmark

To evaluate the ability of asiaticoside to enhance the effectiveness of MSLN-targeted CAR-T cells in treating ovarian cancer.
Engineered MSLN-specific CAR-T cells for therapy.
Conducted in vitro co-culture assays and in vivo xenograft models.
Analyzed transcriptional changes using RNA sequencing.
Investigated TGF-β/SMAD signaling mechanisms.
Evaluated efficacy and safety in NCG mice with ovarian tumors.
Asiaticoside significantly improved CAR-T cell cytotoxicity.
Reduced expression of exhaustion markers PD-1, TIM-3, and LAG-3.
Inhibition of TGF-β signaling pathways observed.
Combination therapy led to greater tumor suppression compared to CAR-T alone.
No systemic toxicity or organ damage observed.

No takes yet. Share an insight, caveat, or question.

Reveals that asiaticoside enhances antitumor effects of MSLN-targeted CAR-T cells in ovarian cancer, suggesting improved treatment options.

Jiang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Reveals that asiaticoside enhances antitumor effects of MSLN-targeted CAR-T cells in ovarian cancer, suggesting improved treatment options.